dr. rini discusses the vegf targeted agent axitinib
Published 12 years ago • 714 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
0:38
dr. rini explains the axitinib integration process
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
50:21
the multifaceted aspects of nutrition
-
1:02:30
the new science of contrast associated nephropathy
-
46:29
giant cell arteritis: past and future by bonnie keung m.d.
-
0:45
dr. rini on the progression of advanced rcc therapy
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
11:56
axitinib is the new standard of care in 2nd-line: pro brian i. rini, m.d.
-
1:03
dr. hutson discusses the phase iii atlas study in rcc
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
6:59
single-agent axitinib therapy in patients with unresectable recurrent cancer - paul swiecicki
-
3:43
the rationale behind combination therapy in mrcc
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
3:01
potential immunotherapy combinations in rcc
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
1:22
dr. mcdonald explains approved angiogenesis inhibitors
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma